Who
Paul A. Mahon
EVP & General Counsel
Company insider
Files Form 4 as: EVP & General Counsel, United Therapeutics.
In numbers
- Trades disclosed
- 2,057
- Buys
- 0
- Sells
- 302
- Bought
- $0
- Sold
- $420.1M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 5 Jan 2006
- Last trade
- 15 Oct 2026
- Last filed
- 16 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Oct 2026filed 16 Oct 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Code M | $1.2M8,300 at $146.03 | filing |
| 15 Oct 2026filed 16 Oct 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $145K268 at $541.64 | filing |
| 15 Oct 2026filed 16 Oct 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.0M1,924 at $542.49 | filing |
| 15 Oct 2026filed 16 Oct 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.1M1,983 at $543.56 | filing |
| 15 Oct 2026filed 16 Oct 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $431K791 at $544.85 | filing |
| 15 Oct 2026filed 16 Oct 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.4M2,615 at $545.69 | filing |
| 15 Oct 2026filed 16 Oct 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $393K719 at $546.56 | filing |
| 15 Oct 2026filed 16 Oct 2026 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,300 at $0.00 | filing |
| 1 Oct 2026filed 1 Oct 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Code M | $1.2M8,300 at $146.03 | filing |
| 1 Oct 2026filed 1 Oct 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $471K823 at $572.25 | filing |
| 1 Oct 2026filed 1 Oct 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $92K160 at $573.15 | filing |
| 1 Oct 2026filed 1 Oct 2026 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,300 at $0.00 | filing |
| 1 Oct 2026filed 1 Oct 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $491K880 at $558.30 | filing |
| 1 Oct 2026filed 1 Oct 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $829K1,480 at $560.19 | filing |
| 1 Oct 2026filed 1 Oct 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $438K780 at $561.87 | filing |
| 1 Oct 2026filed 1 Oct 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $833K1,480 at $563.09 | filing |
| 1 Oct 2026filed 1 Oct 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $227K400 at $566.41 | filing |
| 1 Oct 2026filed 1 Oct 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $409K720 at $567.76 | filing |
| 1 Oct 2026filed 1 Oct 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $421K739 at $569.15 | filing |
| 1 Oct 2026filed 1 Oct 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $478K838 at $570.90 | filing |
The newest 500 lines are listed; the numbers count every line.
News
Share Repurchase Plan Announced by United Therapeutics (NASDAQ:UTHR) Board of DirectorsUTHR · tickerreport.com · 23 Oct 2026United Therapeutics (NASDAQ:UTHR) Price Target Raised to $725.00UTHR · dailypolitical.com · 22 Oct 2026Contrasting Xenon Pharmaceuticals (NASDAQ:XENE) and United Therapeutics (NASDAQ:UTHR)UTHR · dailypolitical.com · 18 Oct 2026
0 headlines in the last 90 days name Paul A. Mahon; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.